Driven by our vision, “Make a Difference for the World”, we are advancing differentiated programs in mucosal vaccines, oncolytic viruses, antiviral therapeutics, and gene therapies, translating proprietary viral engineering capabilities into clinical-stage solutions.
Our vaccine pipeline is built on advanced mucosal immunization technologies designed to enhance local immune responses and provide early protection at the site of infection. In parallel, we are advancing novel oncolytic virus and gene therapy programs, leveraging our expertise in viral vector engineering, targeted gene delivery, and rational viral design to overcome key challenges in therapeutic development.
DIFF Biotech has established a strong intellectual property foundation supporting its technology platforms and product pipelines, with more than 90 patent applications filed, including over 10 international PCT applications. Our innovations have been recognized with the Excellent Award at the 23rd China Patent Awards, demonstrating our commitment to scientific excellence and technological advancement.
Beyond internal pipeline development, DIFF Biotech collaborates with pharmaceutical companies, biotechnology companies, and research institutions worldwide through flexible partnership models, including technology collaboration, co-development, licensing, and translational research partnerships. By combining our proprietary viral engineering platforms with global expertise, we aim to accelerate the development and delivery of transformative biomedical innovations.